Clinical Trials for Marginal Zone Lymphoma

Find clinical trials for marginal zone lymphoma. Discover research opportunities and treatment options in your area.

46 Active Trials Found

Showing 46 trials on this page

Page 1 of 3

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

NCT ID: NCT06792825

This clinical trial, called HM2023-43, is studying a new treatment combination for patients with two types of lymphoma: follicular lymphoma (FL) and marginal zone lymphoma (MZL). The researchers wa...

Not yet recruiting

Phase: PHASE2 Type: interventional

A Phase 2 Study of Epcoritamab, Zanubrutinib, and Rituximab (EZR) for Treatment of Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma

NCT ID: NCT06563596

This clinical trial is studying a combination of three medications—epcoritamab, zanubrutinib, and rituximab— to see how well they work together in treating patients with relapsed or refractory foll...

Phase: PHASE2 Type: interventional Locations: Boston, Massachusetts, United States, Boston, Massachusetts, United States

Allo HSCT Using RIC and PTCy for Hematological Diseases

NCT ID: NCT05805605

This clinical trial is looking at a new approach to treating certain blood cancers, including various types of leukemia and lymphoma. The study is specifically evaluating a method called "Allo HSCT...

Phase: PHASE2 Type: interventional Locations: Minneapolis, Minnesota, United States

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

NCT ID: NCT06860880

This clinical trial, titled "Combating Cancer-Related Fatigue: A Personalized Supportive Care Program," is designed to help patients with certain types of indolent lymphomas, including chronic lymp...

Phase: NA Type: interventional Locations: Chapel Hill, North Carolina, United States

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT ID: NCT05006716

This clinical trial is studying a new treatment called BGB-16673 for patients with specific types of B-cell cancers, such as Marginal Zone Lymphoma, Follicular Lymphoma, and Chronic Lymphocytic Leu...

Phase: PHASE1 Type: interventional Locations: New York, New York, United States, Rochester, Minnesota, United States +197 more

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT ID: NCT05100862

This clinical trial is studying two different treatment combinations for patients with certain types of lymphoma that have returned or not responded to previous treatments. The first combination be...

Phase: PHASE3 Type: interventional Locations: Seattle, Washington, United States, Varese, , Italy +503 more

A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas

NCT ID: NCT07029217

This clinical trial is studying whether a very low dose of radiation therapy (called VLDRT) can effectively treat people with certain types of slow-growing blood cancers called follicular lymphoma ...

Phase: PHASE3 Type: interventional Locations: New York, New York, United States, Harrison, New York, United States +5 more

SynKIR-310 for Relapsed/Refractory B-NHL

NCT ID: NCT06544265

The SynKIR-310 trial is a research study aimed at evaluating a new treatment called SynKIR-310 for adults with certain types of B-cell lymphoma that have not responded to previous therapies or have...

Phase: PHASE1 Type: interventional Locations: Fairway, Kansas, United States, Portland, Oregon, United States +1 more

64Cu-LLP2A for Imaging Hematologic Malignancies

NCT ID: NCT06636175

This clinical trial is studying a new imaging agent called 64Cu-LLP2A, which is designed to help doctors see and understand certain blood cancers better. The trial focuses on patients with conditio...

Phase: EARLY_PHASE1 Type: interventional Locations: Saint Louis, Missouri, United States, Saint Louis, Missouri, United States

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

NCT ID: NCT06533579

This clinical trial is studying a new treatment called VNX-101 for patients with a type of blood cancer known as B-cell acute lymphoblastic leukemia (ALL) that has not responded to previous therapi...

Phase: PHASE1 Type: interventional Locations: Valhalla, New York, United States, Duarte, California, United States +5 more

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

NCT ID: NCT06796998

This clinical trial is studying a new treatment called Epcoritamab for patients with Marginal Zone Lymphoma (MZL), a type of blood cancer that can occur in different forms. The main goal is to see ...

Not yet recruiting

Phase: PHASE2 Type: interventional Locations: Miami, Florida, United States

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

NCT ID: NCT05296070

This clinical trial is studying a new treatment called loncastuximab tesirine for patients with relapsed or refractory marginal zone lymphoma (MZL), a type of immune cell cancer. The researchers wa...

Phase: PHASE2 Type: interventional Locations: Atlanta, Georgia, United States, Nashville, Tennessee, United States +2 more

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

NCT ID: NCT06340737

This clinical trial is studying a new treatment called CD22 CAR T-cell therapy for adults with certain types of blood cancers known as B cell lymphomas. These cancers include follicular lymphoma, m...

Phase: PHASE1 Type: interventional Locations: Palo Alto, California, United States

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

NCT ID: NCT05602363

This clinical trial is studying a new oral medication called AS-1763 (docirbrutinib) for patients with certain types of blood cancers, including chronic lymphocytic leukemia (CLL), small lymphocyti...

Phase: PHASE1 Type: interventional Locations: Worcester, Massachusetts, United States, Miami Beach, Florida, United States +12 more

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT ID: NCT05294731

This clinical trial is studying a new treatment called BGB-16673 for patients with certain types of B-cell cancers, including Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. The goal is to f...

Phase: PHASE1 Type: interventional Locations: Beijing, Beijing, China, Nanjing, Jiangsu, China +40 more

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

NCT ID: NCT06350318

This clinical trial is investigating the safety and effectiveness of two medications, rituximab and zanubrutinib, for patients with certain types of untreated B-cell lymphomas, specifically margina...

Phase: PHASE2 Type: interventional Locations: Tampa, Florida, United States

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

NCT ID: NCT04883437

This clinical trial is studying a combination of two medications, acalabrutinib and obinutuzumab, to see how effective they are in treating patients with certain types of previously untreated indol...

Phase: PHASE2 Type: interventional Locations: Atlanta, Georgia, United States

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

NCT ID: NCT04792502

This clinical trial, called BrUOG-401, is studying a new treatment approach for adults with two types of blood cancers: follicular lymphoma and marginal zone lymphoma. The trial is specifically loo...

Phase: PHASE2 Type: interventional Locations: New Brunswick, New Jersey, United States, New Haven, Connecticut, United States +1 more

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

NCT ID: NCT06151730

The HALT Study is looking at how to manage high blood pressure in patients with certain types of B-cell cancers, such as chronic lymphocytic leukemia and mantle cell lymphoma, who are starting trea...

Type: observational Locations: Rochester, Minnesota, United States

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

NCT ID: NCT04186520

This clinical trial is investigating a new treatment using specially modified immune cells, called CAR-20/19-T cells, to help patients with certain types of blood cancers, such as Non-Hodgkin Lymph...

Phase: PHASE1 Type: interventional Locations: Milwaukee, Wisconsin, United States

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions